Asthma
Conditions
Keywords
mepolizumab, omalizumab, SB-240563, Severe Asthma, reslizumab
Brief summary
This will be a non-drug interventional cross-sectional study, where the screening visit and study visit can occur on the same day. Investigational product will not be administered. Approximately 790 subjects with severe asthma will be screened to achieve a total of at least 750 evaluable study subjects. The study will not include a run-in or follow-up period. This study will provide a more reliable description of the severe asthma patient landscape with respect to the potential eligibility for treatment with mepolizumab, omalizumab, and reslizumab. This study aims to estimate the potential overlap of patients eligible for treatment with mepolizumab and those eligible for treatment with omalizumab and/or reslizumab. Additionally, the current study will also ascertain and describe reslizumab eligibility with respect to both mepolizumab and omalizumab, in the severe asthma patient population.
Interventions
DRUGShort Acting Beta Agonist (SABA)
Participants requiring a spirometry measurement will be administered a SABA in a metered dose inhaler (MDI) during the reversibility assessments
Sponsors
GlaxoSmithKline
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* At least 12 years of age at study visit. * Participants eligible for enrolment and entry into the study must meet the following definition of severe asthma, which is based on the definition of severe asthma described in the European Respiratory Society/ American Thoracic Society (ERS/ATS) Guidelines for severe asthma: Asthma which requires treatment with guideline suggested medications for Global Initiative for Asthma (GINA) steps 4-5 asthma for the previous year (i.e., at least 12 months). Patients must be treated with high dose ICS PLUS at least one of the following: LABA, leukotriene modifier, theophylline, or continuous or near continuous systemic corticosteroid (i.e., maintenance systemic corticosteroid for ≥50% of the previous year). SPECIAL CIRCUMSTANCE: If patient is on a fixed dose combination medication, then the maximum recommended dose of the ICS/LABA combination per local label is acceptable. * Able to give written informed consent prior to participation in the study, which will include the ability to comply with the requirements and restrictions listed in the consent form. Participants must be able to read, comprehend, and write at a level sufficient to complete study related materials. A parent or legal guardian must provide informed consent for participants less than 18 years of age at study visit (or less than minimum age to be considered an adult per local laws).
Exclusion criteria
Participants who have participated in an interventional clinical trial for asthma within the past 12 months prior to Visit 1 (NOTE: subjects participating in an observational study where an investigational product or procedure is not administered will not be subject to this
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of severe asthma patients eligible for one or more biologic treatments for asthma | Day 1 | Biologic treatments for asthma will include mepolizumab (anti-Interleukin \[IL\] 5), omalizumab (anti-immunoglobulin E \[IgE\]), and reslizumab (anti-IL5). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Descriptive statistics for asthma Control Questionnaire (ACQ-5) | Day 1 | — |
| Mean and median frequency of planned and unplanned asthma-related healthcare resource utilization in the prior 12 months | Day 1 | — |
| Mean and median Charlson Comorbidity Index score | Day 1 | The Charlson Comorbidity Index is a score that is based on age and the presence of 19 comorbidities. The mean and median Charlson Comorbidity Index score will be calculated and reported |
| Mean pre-bronchodilator forced expiratory volume in 1 sec (FEV1)/forced vital capacity (FVC) ratio | Day 1 | Spirometry assessment will be performed with mean pre- and post-bronchodilator FEV1/FVC, pre- and post-bronchodilator FEV1 and FVC, and airway reversibility |
| Mean post-bronchodilator FEV1/FVC ratio | Day 1 | Spirometry assessment will be performed with mean pre- and post-bronchodilator FEV1/FVC, pre- and post-bronchodilator FEV1 and FVC, and airway reversibility |
| Mean pre-bronchodilator FEV1 | Day 1 | Spirometry assessment will be performed with mean pre- and post-bronchodilator FEV1/FVC, pre- and post-bronchodilator FEV1 and FVC, and airway reversibility |
| Mean post-bronchodilator FEV1 | Day 1 | Spirometry assessment will be performed with mean pre- and post-bronchodilator FEV1/FVC, pre- and post-bronchodilator FEV1 and FVC, and airway reversibility |
| Mean pre-bronchodilator FVC | Day 1 | Spirometry assessment will be performed with mean pre- and post-bronchodilator FEV1/FVC, pre- and post-bronchodilator FEV1 and FVC, and airway reversibility |
| Mean and median levels of specific IgE | Day 1 | — |
| Mean and median levels of blood eosinophils | Day 1 | — |
| Mean and median levels of total IgE | Day 1 | — |
| Descriptive statistics for St. George's Respiratory Questionnaire (SGRQ) | Day 1 | — |
| Descriptive statistics for Asthma Quality of Life Questionnaire (AQLQ-S) | Day 1 | — |
| Descriptive statistics for EuroQol 5D (EQ-5D-5L) | Day 1 | — |
| Descriptive statistics for Work Productivity and Activity Impairment Index: General Health (WPAI-GH) | Day 1 | — |
| Descriptive statistics for Asthma Symptom Utility Index (ASUI) | Day 1 | — |
| Mean post-bronchodilator FVC | Day 1 | Spirometry assessment will be performed with mean pre- and post-bronchodilator FEV1/FVC, pre- and post-bronchodilator FEV1 and FVC, and airway reversibility |
Countries
Australia, Canada, France, Germany, United Kingdom, United States
Outcome results
None listed